{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:47:24Z","timestamp":1786992444943,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jgar.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:46:36Z","timestamp":1772984796000},"page":"121-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical outcomes of linezolid monotherapy vs. combination therapy in vancomycin-resistant enterococcal infections"],"prefix":"10.1016","volume":"48","author":[{"given":"Prarin","family":"Siriwattanakowit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakawan","family":"Charoensataporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tossaroot","family":"Theeranuwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poramet","family":"Sirirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonthapohn","family":"Laohakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichai","family":"Santimaleeworagun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-6834","authenticated-orcid":false,"given":"Dhitiwat","family":"Changpradub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5265-5808","authenticated-orcid":false,"given":"Jatapat","family":"Hemapanpairoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.03.005_bib0001","series-title":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","year":"2024"},{"key":"10.1016\/j.jgar.2026.03.005_bib0002","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/antibiotics14050522","article-title":"Vancomycin-resistant E. faecium: addressing global and clinical challenges","volume":"14","author":"Radford-Smith","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.03.005_bib0003","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jcpt.13383","article-title":"Prevalence of vancomycin-resistant enterococci in Asia\u2014a systematic review and meta-analysis","volume":"46","author":"Shrestha","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jgar.2026.03.005_bib0004","series-title":"Antimicrobial resistance surveillance report","year":"2026"},{"key":"10.1016\/j.jgar.2026.03.005_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/antibiotics10020105","article-title":"Does vancomycin resistance increase mortality? Clinical outcomes and predictive factors for mortality in patients with Enterococcus faecium infections","volume":"10","author":"Hemapanpairoa","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.03.005_bib0006","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2147\/IDR.S208298","article-title":"Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect","volume":"12","author":"Hemapanpairoa","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2026.03.005_bib0007","article-title":"Therapeutics for vancomycin-resistant enterococcal bloodstream infections","volume":"36","author":"Cairns Kelly","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2026.03.005_bib0008","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.cmi.2020.10.029","article-title":"How do I manage a patient with enterococcal bacteraemia?","volume":"27","author":"Rosselli Del Turco","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.03.005_bib0009","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/phar.1922","article-title":"Role of combination antimicrobial therapy for vancomycin-resistant Enterococcus faecium infections: review of the current evidence","volume":"37","author":"Yim","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2026.03.005_bib0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diagmicrobio.2013.07.012","article-title":"In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates","volume":"77","author":"Tang","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2026.03.005_bib0011","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.03.005_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2023.2181160","article-title":"Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations","volume":"16","author":"Cattaneo","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jgar.2026.03.005_bib0013","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jmii.2017.08.025","article-title":"Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia","volume":"51","author":"Ye","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2026.03.005_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jmii.2011.11.005","article-title":"Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan","volume":"45","author":"Chou","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2026.03.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00871-21","article-title":"Dose optimization of combined linezolid and fosfomycin against Enterococcus by using an In vitro pharmacokinetic\/pharmacodynamic model","volume":"9","author":"Mao","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.03.005_bib0016","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jinf.2005.05.022","article-title":"Treatment of prosthetic valve infective endocarditis due to multi-resistant gram-positive bacteria with linezolid","volume":"52","author":"Wareham","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2026.03.005_bib0017","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/00365548.2012.717711","article-title":"Vancomycin-resistant Enterococcus faecium meningitis in adults: case series and review of the literature","volume":"45","author":"Knoll","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jgar.2026.03.005_bib0018","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1086\/517221","article-title":"Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin","volume":"28","author":"Noskin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.03.005_bib0019","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12877-025-06241-9","article-title":"Renal function affects the plasma concentration and hematological toxicity of linezolid in elderly patients: a propensity-matched cohort analysis","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jgar.2026.03.005_bib0020","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3947\/ic.2021.0034","article-title":"Optimization of linezolid dosing regimens for treatment of vancomycin-resistant enterococci infection","volume":"53","author":"Santimaleeworagun","year":"2021","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jgar.2026.03.005_bib0021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/futurepharmacol5040061","article-title":"Effectiveness and safety of Linezolid as continuous infusion versus intermittent infusion in critically ill patients: a pilot study","volume":"5","author":"Hui","year":"2025","journal-title":"Future Pharmacol"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:28:33Z","timestamp":1781350113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"alternative-id":["S2213716526000366"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.03.005","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of linezolid monotherapy vs. combination therapy in vancomycin-resistant enterococcal infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}